HTHelen Toledano

Helen Toledano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helen Toledano has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood

    by Liana Nobre, Vijay Ramaswamy, Christina Coleman, Girish Dhall, Akanksha Senapati, Helen Toledano, Nada Jabado, Eric Bouffet, Lucie Lafay-Cousin


  • Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1

    by Helen Toledano, Gad Dotan, Rivka Friedland, Rony Cohen, Iftach Yassur, Hagit Toledano-Alhadef, Shlomi Constantini, Mika Shapira Rootman

    Introduction Plexiform neurofibromas (PNF) in neurofibromatosis type 1 (NF1) are usually diagnosed in childhood and can grow rapidly during this period. In 10% of patients, PNF involve the orbital-periorbital area and may cause visual problems including glaucoma, visual loss from amblyopia (deprivational, strabismic, or refractive), optic nerve compression, or keratopathy. Ptosis, proptosis, and facial disfigurement lead to social problems and decreased self-esteem. Complete surgical removal involves significant risks and mutilation, and regrowth after debulking is not uncommon. Inhibitors of the RAS/MAPK pathway have recently been investigated for their activity in PNF. We administered the oral MEK inhibitor trametinib to five young children with NF1 and PNF of the orbital area, with visual compromise and progressive tumor growth; and followed them clinically and by volumetric MRI. Methods Treatment was initiated at a mean age of 26.8 months (SD ± 12.8) and continued for a median 28 months (range 16–51). Doses were 0.025 mg/kg/day for children aged > 6 years and 0.032 mg/kg/day for those aged < 6 years. Results Volumetric MRI measurements showed a reduction of 2.9–33% at 1 year after treatment initiation, with maximal reductions of 44% and 49% in two patients, at 44 and 36 months, respectively. No change in visual function was recorded during treatment. One child reported decreased orbital pain after 2 weeks; and another, with involvement of the masseters, had increased ability to chew food. Toxicities were mostly to skin and nails, grades 1–2. Conclusions Trametinib can decrease tumor size in some young children with orbital PNF and may prevent progressive disfigurement.


  • MBRS-27. DIFFERENCES IN RNA AND MIRNA EXPRESSION BETWEEN PTCH AND SUFU MUTATED MEDULLOBLASTOMA IN TWO PATIENTS WITH GORLIN’S SYNDROME

    by Sivan Gershanov, Helen Toledano, Nitza Goldenberg-Cohen, Mali Salmon-Divon

    A percentage of sonic hedgehog (SHH) medulloblastomas will carry a germline mutation in PTCH1 (upstream) or SUFU (downstream) as part of Gorlin’s syndrome. It has been suggested that the tendency to develop medulloblastoma is greater in those with SUFU and that the syndromic features are different depending on the gene involved. We compared the gene and microRNA expression profile of the tumors of two patients with germline mutations - one in PTCH and one in SUFU. We performed RNA and microRNA sequencing from fresh tumor samples followed by ingenuity pathway analysis. We identified several differences in expression of genes and microRNA: the miRNAs miR-130a-3p and miR-181-5p showed lower expression in the SUFU sample with resultant increased expression of DICER1 either directly or indirectly. Other genes that exhibit decreased expression in the SUFU sample included Connexin involved in Gap junction signaling and Metalloproteinase involved in axonal guidance signaling. Genes that display higher expression in the SUFU sample included GABAR-A in the GABA receptor signaling pathway and Cahedrin in the beta-catenin signaling pathway. These findings need confirmation in a larger sample of tumors and may help to find treatable molecular targets for these types of medulloblastoma. This is vital since radiation - a standard component of treatment for medulloblastoma - is contraindicated in Gorlin’s due to the risk of basal cell carcinoma. In addition SHH inhibitors are ineffective for SUFU medulloblastoma as they inhibit upstream of the mutation.

  • EPEN-25. KANSL1 GAIN AND FUSION - A NOVEL ALTERATION IN CHILDHOOD EPENDYMOMA

    by Yulia Margolin-Miller, Helen Toledano, Lital Sela-Tzuriano, Michal Hameiri-Grossman, Shalom Michowiz, Suzanna Fichman-Horn, Meora Feinmesser, Stefan Pfister, Hendrik Witt, Isaac Yaniv, et al.

    Ependymoma is a malignant pediatric brain tumor, often incurable with current treatment regimens. We aimed to identify new genes involved in pediatric ependymoma using copy number SNP array analysis. We analyzed 34 primary tumors, in 10 cases we analyzed the paired diagnosis-relapse samples and in 5 of them we also analyzed the corresponding peripheral blood (PB) sample. The most prevalent alterations identified were gain of 8q (18%), deletion of 10q (18%), gain of 11q (12%) and gain of 17q (53%). The locus of the 17q21.31 gain contains only one gene - KANSL1 (KAT8 regulatory NSL complex subunit 1) gene. The gain affected exons 1–4 of the gene. This gain was identified in 9 out of the 10 (90%) relapse samples and in all of the PB samples. The gain was validated at the RNA level and a significant overexpression of KANSL1 mRNA was detected in the samples exhibiting gain versus the samples with normal copy number (p=0.04). KANSL1 is part of the NSL complex which functions as a histone acetyltransferase. The 17q21.31 locus contains a common inversion duplication polymorphism enriched in European populations. Recently, a new fusion was discovered in high frequencies in adult malignancies between KANSL1 and ARL17, termed KANSARL, both located on 17q21.31. KANSARL fusion was detected in 71% of our samples. All the samples that exhibited gain of KANSL1 were positive for the KANSARL fusion. Our results suggest that the gain precedes the formation of the fusion which may be a predisposing event in ependymoma.

  • ATRT-04. LATE DEVELOPMENT OF METACHRONOUS ATYPICAL TERATOID/RHABDOID TUMORS (AT/RTS) OR MALIGNANT RHABDOID TUMOR (MRT) IN THREE PATIENTS WITH GERMLINE SMARCB1 MUTATIONS

    by Anne Bendel, Helen Toledano, Ian Cohen, Susan Chi, Jaclyn Biegel

    Atypical teratoid/rhabdoid tumor (AT/RT) and malignant rhabdoid tumor (MRT) are aggressive malignancies that typically occur in children < 3 years of age and historically have a survival of < 30%. Approximately 25% of patients harbor inactivating germline alterations in SMARCB1, which predispose carriers to develop rhabdoid tumors (RTs) between birth to 5 years (median 5 months). Surveillance guidelines for carriers of SMARCB1 (or SMARCA4) alterations recommend screening with brain MRI, abdominal ultrasound and total body MRI up to 5 years of age. We present 3 survivors of AT/RT with germline alterations in SMARCB1 who developed late primary (metachronous) RTs. Case 1 was diagnosed with a posterior fossa (PF) AT/RT at 3.5 years and developed a metachronous temporal lobe AT/RT at 17.8 years. Case 2 was diagnosed with a PF AT/RT and synchronous renal MRT at 2 months and developed a metachronous thalamic AT/RT at 8 years. Case 3 was diagnosed at 9 weeks with a lateral ventricle AT/RT and developed a metachronous disseminated retroperitoneal MRT at 11.5 years. Genetic analyses confirmed the 2 AT/RTs in case 1, the 2 AT/RTs and 1 MRT in case 2, and the 1 AT/RT and 1 MRT in case 3 to be distinct primary tumors. Due to advances in the treatment of AT/RT and MRT, survival rates are improving. The 3 cases presented in this report suggest that tumor surveillance beyond 5 years of age is indicated for patients with germline alterations who are predisposed to cancer.


  • MBCL-12. METASTATIC DISEASE IN THE SUPRASELLAR AREA AT DIAGNOSIS IN MEDULLOBLASTOMA

    by Helen Toledano, Mika Rootman, Shalom Michowiz, Osnat Konen

    Metastatic disease at presentation of medulloblastoma is present in approximately 30% and confers a poor prognosis. Metastases are usually spinal and occult intracranial metastases maybe overlooked. The infundibular recess of the third ventricle is a known site of metastases in various tumors particularly at relapse. The diagnostic brain and spinal imaging of all our medulloblastoma patients from 1/2007 to 12/2017 were assessed by 2 radiologists blinded to patient outcome. We collected clinical data retrospectively from the charts.

  • Open Access

    Optimizing the process of fertility preservation in pediatric female cancer patients – a multidisciplinary program

    by Irit Ben-Aharon, R. Abir, G. Perl, J. Stein, G. Gilad, H. Toledano, S. Elitzur, G. Avrahami, A. Ben-Haroush, G. Oron, et al.

    Current evidence indicates sub-optimal incidence of fertility preservation (FP) in eligible patients. We present herein our designated multidisciplinary program for FP in pediatric and adolescent population and present our data on FP in female patients. Pediatric patients (age 0–18) who were candidate for highly gonadotoxic treatments were referred to FP program for a multidisciplinary discussion and gonadal risk-assessment followed by either oocyte cryopreservation or ovarian cryopreservation (OCP) for female patients, and sperm banking for male patients. The OCP protocol consists of aspiration of oocytes from small antral follicles and in-vitro maturation followed by cryopreservation, as well as ovarian tissue cryopreservation. The establishment of a designated FP program resulted in a significant increase in referral and subsequent FP procedures of all eligible patients. Sixty-two female patients were referred for FP discussion during a period of 36 months; 41 underwent OCP; 11 underwent oocyte cryopreservation and six were declined due to parental decision. The median age was 13.2y (range 18 months-18y). Thirty-two (51.6 %) were chemotherapy-naïve. Seventeen patients (27 %) had sarcoma, 16 patients (26 %) had acute leukemia. The mean number of mature oocytes that were eventually vitrified was significantly higher in chemotherapy-naïve patients compared with chemotherapy-exposed patients (mean 12 oocytes (1–42) versus 2 (0–7)). Multidisciplinary programs that encompass experts of all relevant fields, skilled laboratory resources and a facilitated path appear to maximize the yield. We observed a considerable higher referral rates following launching a designated program and earlier OCP in chemo-naïve patients that culminated in a better fertility preservation procedure.


  • Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G‐CSF following high dose craniospinal irradiation for medulloblastoma in a young child

    by Helen Toledano, Anat Yahel, Ian J. Cohen, Isaac Yaniv, Jerry Stein

    Contemporary protocols for the treatment of malignant brain tumors such as medulloblastoma (MB) in children, often involve craniospinal irradiation (CSI) at diagnosis followed by serial courses of high dose chemotherapy and autologous hematopoietic stem cell support. Patients often require several pheresis procedures in order to collect sufficient stem cells for this type of treatment, particularly if they have already had CSI. We describe the successful mobilization, collection and subsequent transplant of a 7‐year‐old female with medulloblastoma after recent CSI using granulocyte colony stimulating factor (G‐CSF) and the CXCR4 antagonist AMD3100 after a failed previous mobilization attempt using G‐CSF alone. Pediatr Blood Cancer 2010;54:613–615.


  • Molecular characterization of three novel Fanconi anemia mutations in Israeli Arabs

    by Hannah Tamary, Orly Dgany, Helen Toledano, Zvi Shalev, Tatyana Krasnov, Lea Shalmon, Tali Schechter, Dani Bercovich, Dina Attias, Ruth Laor, et al.

    In a previous study, we investigated the molecular basis of Fanconi anemia (FA) in 13 unrelated Israeli Jewish FA patients and identified four ethnicity specific mutations. In the present study we extended our study to Israeli Arab patients. We studied three consanguineous families with nine FA patients and an additional unrelated patient. DNA single-strand conformation polymorphism of each exon of the FANCA and FANCG genes was followed by sequence analysis of the aberrantly migrating fragments and by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the splice-site mutations identified. Three unique disease-causing mutations were identified: (i) FANCA gross deletion of exons 6-31; (ii) FANCA splice-site mutation IVS 42-2A>C; (iii) FANCG splice-site mutation IVS4+3A>G. Sequence analysis of the FANCA gross deletion revealed recombination between two highly homologous Alu elements. cDNA analysis of the two splice mutations suggested intron 42 retention in FANCA IVS 42-2A>C and exon 4 skipping in FANCG IVS4+3A>G. The clinical condition of eight patients with FANCA mutations was severe. Two unique FANCA mutations and one FANCG mutation were identified in Israeli Arab FA patients. Deletion of FANCA exon 6-31 as in previously described gross deletions was within introns rich in Alu repeats. To the best of our knowledge, the FANCA IVS 42-2A>C mutation is the first in this gene to result in intron retention. Further analysis of FA mutations will enable prenatal diagnosis and a rational therapeutic approach including frequent monitoring and early bone marrow transplantation.